Predicting prostate cancer many years before diagnosis: how and why?

Evidence of reduced prostate cancer mortality from randomized trials in Europe supports early detection of prostate cancer with prostate-specific antigen (PSA). Yet PSA screening has generated considerable controversy: it is far from clear that the benefits outweigh risks, in terms of overdiagnosis...

Description complète

Détails bibliographiques
Auteurs principaux: Vickers, A, Lilja, H
Format: Journal article
Langue:English
Publié: 2012

Documents similaires